Neogenesis Biotechnology Corporation
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. Precision Cell Testing Laboratory: Dr. Chao-Hung Yen, Chairman of Neogenesis Biotechnology Corporation, introduced advanced regenerative medicine technology from the United States to Taiwan in 2019. However, because Taiwan lacked comprehensive cell testing to provide hospital physicians with precise data to understand patients' current cellular conditions—which is essential for achieving effective cell therapy—the company engaged in an industry-academia collaboration with Taipei Medical University from 2020 to 2022 to develop a series of precision testing methods related to regenerative medicine.
2. Operation of Regenerative Medicine Clinics
3. Cell Preparation Research and Development Center: Providing research consultation for immune cells (NK, CIK, DC); application and research of stem cells (MSC), mitochondria, and exosomes; research on fibroblasts and adipose-derived stem cells, and collaboration with medical aesthetic clinics; storage of baby cord blood and umbilical cord MSCs; precision analysis and storage of adult immune cells.
4. Research and Application of Biologics
(The content above was translated by AI.)
2. Operation of Regenerative Medicine Clinics
3. Cell Preparation Research and Development Center: Providing research consultation for immune cells (NK, CIK, DC); application and research of stem cells (MSC), mitochondria, and exosomes; research on fibroblasts and adipose-derived stem cells, and collaboration with medical aesthetic clinics; storage of baby cord blood and umbilical cord MSCs; precision analysis and storage of adult immune cells.
4. Research and Application of Biologics
(The content above was translated by AI.)
Founded Year
2019
Unified Business No.
83496225
Status
Active
Number of Employees
24
Total Paid-in
Capital
50,400,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Dr. Chao-Hung Yen, the founder of Xing Chuang Biotech, began providing global medical services in 2010. Headquartered in California, USA, the company is a medical group that brings together medical experts, scientific research experts, and equipment experts. Over the past few years, it has been dedicated to international medical-related industries, with its reach extending to China, Southeast Asia, the United States, and beyond. At the end of 2019, the group returned to Taiwan to develop advanced regenerative medicine, integrating with Taiwan's cell industry to bring advanced cell therapy technology from the United States into Taiwan.
(The content above was translated by AI.)
(The content above was translated by AI.)
